These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
994 related articles for article (PubMed ID: 37637244)
1. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244 [TBL] [Abstract][Full Text] [Related]
2. Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(9):1-293. PubMed ID: 39364436 [TBL] [Abstract][Full Text] [Related]
3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy. Rognoni C; Lorusso D; Costa F; Armeni P Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713 [TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751 [TBL] [Abstract][Full Text] [Related]
6. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488 [TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286 [TBL] [Abstract][Full Text] [Related]
8. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868 [TBL] [Abstract][Full Text] [Related]
9. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559 [TBL] [Abstract][Full Text] [Related]
10. Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(1):1-142. PubMed ID: 34055109 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA. Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868 [TBL] [Abstract][Full Text] [Related]
12. Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(12):1-134. PubMed ID: 33240453 [TBL] [Abstract][Full Text] [Related]
14. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL; Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. Penn CA; Wong MS; Walsh CS JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974 [TBL] [Abstract][Full Text] [Related]
16. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273 [TBL] [Abstract][Full Text] [Related]
17. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455 [TBL] [Abstract][Full Text] [Related]
18. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770 [TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
20. Osseointegrated Prosthetic Implants for People With Lower-Limb Amputation: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2019; 19(7):1-126. PubMed ID: 31911825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]